🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The GLP-1 family of drugs have exceeded all expectations, beyond diabetes and obesity. Now there's a pre-clinical GLP-1 and NMDA dual receptor drug with many enhanced features that could prove to be another step forward nature nature.com/articles/d4158… nature.com/articles/s4158…

Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in nature today! nature.com/articles/s4158… 1/7 🧵

Our new paper "GLP-1-directed NMDA receptor antagonism for obesity treatment" is out today in nature nature.com/articles/s4158… We describe the engineering and preclinical development of a new drug candidate that targets NMDA receptors in GLP-1 receptor neurons. 1/8 🧵👇

Help us find a Staff Scientist for the Rodent Metabolic Phenotyping Platform! The position provides expert technical support for our users and assists in the planning and performance of mouse experiments using state-of-the-art equipment and surgery facilities in an international

📢 Job alert! The Metabolomics Platform is looking for an engaged and experienced Staff Scientist with extensive experience in mass spectrometry analysis. candidate.hr-manager.net/ApplicationIni…

Online now - the Spotlight "Bridging brain insulin resistance to Alzheimer’s pathogenesis" from Chen Wenqiang @VBIJohansen and Cristina Legido-Quigley. #BiliverdinReductaseA #BVRA #cognition #neurodegeneration #type2diabetesmellitus authors.elsevier.com/a/1jsGV3S6GfQa…

The Alper Lab Katarzyna Kliza Be sure to catch Spotlights and more on: ✍️the RAS dimers debate ✍️how to combine signaling inhibitors with #PROTACs ✍️brain insulin resistance in diabetes and Alzheimer's (Chen Wenqiang @VBIJohansen Cristina Legido-Quigley) ✍️#nanobodies in cryoEM

Our new paper, "NK2R control of energy expenditure and feeding to treat metabolic diseases," is out today in nature. Here we identify a single receptor that can both peripherally increase energy expenditure and centrally suppress appetite. nature.com/articles/s4158… 1/12 🧵👇

👩‍🔬 𝐈𝐧 𝐍𝐚𝐭𝐮𝐫𝐞: 𝐍𝐞𝐰 𝐰𝐞𝐢𝐠𝐡𝐭 𝐥𝐨𝐬𝐬 𝐝𝐫𝐮𝐠 𝐭𝐚𝐫𝐠𝐞𝐭 𝐛𝐮𝐫𝐧𝐬 𝐞𝐧𝐞𝐫𝐠𝐲 𝐚𝐧𝐝 𝐥𝐨𝐰𝐞𝐫𝐬 𝐚𝐩𝐩𝐞𝐭𝐢𝐭𝐞 – 𝐰𝐢𝐭𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐧𝐚𝐮𝐬𝐞𝐚 𝐚𝐧𝐝 𝐯𝐨𝐦𝐢𝐭𝐢𝐧𝐠 💊 Millions of people around the world benefit from weight loss drugs based on the

🎉 Big news! Group Leader Christoffer Clemmensen has won a prestigious European Research Council (ERC) Consolidator Grant to study the neurobiology of weight rebound & develop therapies for sustained weight loss. 💬 Associate Professor Clemmensen: “This research holds great promise for overcoming one of

Register now for Metabolism Day 2025! 🚀 The annual conference about cardiometabolic diseases and energy control takes place on March 11, 2025 at University of Copenhagen Research in Copenhagen, Denmark. Seven international speakers will join us on the day: 1️⃣ Professor Amalia Gastaldelli |

On #WorldObesityDay, we have contributed a SnapShot to a special Issue on Obesity in Cell Metabolism covering brain actions of the current and emerging weight loss drugs. Jonas Odgaard Petersen Valdemar Brimnes Ingemann Johansen UCPH Healthscience Free access link: authors.elsevier.com/a/1kiaA5WXUlaX…

Just out in Cell Reports Medicine Our latest study on how glucoregulatory hormones, insulin and glucagon, regulate the ghrelin receptor antagonist LEAP2. A superb collaboration led by Valdemar Brimnes Ingemann Johansen alongside Novo Nordisk, Gentofte Hospital, and Steno Diabetes Center. cell.com/cell-reports-m…

In the April issue of Diabetes, we share findings from our mouse model of controlled overfeeding, providing a comprehensive look at energy balance: energy intake, energy expenditure, and fecal energy excretion. American Diabetes Association Read more: diabetesjournals.org/diabetes/artic…

1/3 Excited to share our new review in Nature Metabolism on the therapeutic potential of GLP-1R agonists and GLP-1R/GIPR co-agonists in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. nature.com/articles/s4225…

One of the biggest challenges in treating obesity is that even after weight loss, the body often "remembers" the disease. We propose that targeting inflammation with GLP-1 agonists may be a promising strategy to break this cycle.. Check this out 👇 diabetesjournals.org/diabetes/artic…

After 21 years at my dream job, I’m very sad to announce my early retirement from the National Institutes of Health. My life’s work has been to scientifically study how our food environment affects what we eat, and how what we eat affects our physiology. Lately, I’ve focused on

Is increased hunger really a primary driver of obesity? In this Letter to the Editor in NEJM, Thorkild Sørensen, Mark Friedman and I question the widespread idea that many people develop obesity because they overeat 👇 1/5 nejm.org/doi/full/10.10… NNF Center for Basic Metabolic Research (CBMR) Monell Center

Just out in Nature Neuroscience We have identified a brain circuit that drives safety-seeking behavior, overriding essential needs like feeding. Amazing collaboration with Ole Kiehn, brilliantly led by the now Twitterless Nathalie Krauth. nature.com/articles/s4159…

Shaping the future of cardiometabolic innovation: advances and opportunities. Comment in Nature Metabolism by Zach Gerhart-Hines Thue W Schwartz Juleen R. Zierath and Kei Sakamoto at NNF Center for Basic Metabolic Research (CBMR) nature.com/articles/s4225…